



Press release

Invitation to presentation of BioArctic's Interim Report for the period January - June 2020 on July 10 at 9.30 a.m. CET

Stockholm, Sweden, July 1, 2020 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January – June 2020 on Friday, July 1, 2020, at 08:00 a.m. CET.

BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on July 10, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – June 2020 followed by a Q&A-session.

To attend, please dial-in at one of the numbers below, from:

Sweden: + 46 8 505 583 55
Denmark: + 45 781 501 09
Germany: + 49 692 222 203 77
The Netherlands: + 31 207 219 495
Norway: + 47 239 639 38
Switzerland: + 41 225 675 632
UK: + 44 333 300 9262
US: + 1 833 526 8382

Webcast: <https://tv.streamfabriken.com/bioarctic-q2-2020>

The webcast will afterwards also be available on demand at BioArctic's corporate website <https://www.bioarctic.se/en/section/investors/presentations/>

For more information, please contact:

Oskar Bosson, VP Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se
Tel: + 46 704 10 71 80

This information was submitted for publication at 08:30 a.m. CET on July 1, 2020.



About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and outlicensing potential. BioArctic's Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.